Last 12 months
Inside the activity.
5 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 5 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2022 Filed Oct 6, 2022 23:20 UTC |
Coric VladDirector · Chief Executive Officer
|
PurchaseCommon Shares | 34,459 | $9.89 | $340,968.36 |
DisclosureSEC source: 0001562180-22-007115 · primarydocument.xml · nonDerivative · entry 6 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Marital Trust Disclosed balance after: 264,214 F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.31 - $10.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 23:20 UTC |
Coric VladDirector · Chief Executive Officer
|
PurchaseCommon Shares | 73,005 | $8.82 | $644,130.42 |
DisclosureSEC source: 0001562180-22-007115 · primarydocument.xml · nonDerivative · entry 5 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Marital Trust Disclosed balance after: 229,755 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.30 - $9.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 23:20 UTC |
Coric VladDirector · Chief Executive Officer
|
PurchaseCommon Shares | 54,329 | $11.83 | $642,614.28 |
DisclosureSEC source: 0001562180-22-007115 · primarydocument.xml · nonDerivative · entry 4 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Family Trust Disclosed balance after: 492,212 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.32 - $12.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 23:20 UTC |
Coric VladDirector · Chief Executive Officer
|
PurchaseCommon Shares | 80,907 | $10.83 | $875,842.55 |
DisclosureSEC source: 0001562180-22-007115 · primarydocument.xml · nonDerivative · entry 3 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Family Trust Disclosed balance after: 437,883 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.32 - $11.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 23:20 UTC |
Coric VladDirector · Chief Executive Officer
|
PurchaseCommon Shares | 34,515 | $9.90 | $341,843.46 |
DisclosureSEC source: 0001562180-22-007115 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Family Trust Disclosed balance after: 356,976 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.32 - $10.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 23:20 UTC |
Coric VladDirector · Chief Executive Officer
|
PurchaseCommon Shares | 73,331 | $8.82 | $647,028.75 |
DisclosureSEC source: 0001562180-22-007115 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Family Trust Disclosed balance after: 322,461 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.27 - $9.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 17:36 UTC |
Buten MatthewChief Financial Officer
|
GrantStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007076 · primarydocument.xml · derivative · entry 10 Buten Matthew · CIK 0001898799 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 300,000 shares Expires 2032-10-04 F5 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 4, 2022, 2023, 2024, and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 17:36 UTC |
Buten MatthewChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 11,450 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001562180-22-007076 · primarydocument.xml · derivative · entry 9 Buten Matthew · CIK 0001898799 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 11,450 shares Expires 2032-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 17:36 UTC |
Buten MatthewChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 1,550 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001562180-22-007076 · primarydocument.xml · derivative · entry 8 Buten Matthew · CIK 0001898799 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,550 shares Expires 2032-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 17:36 UTC |
Buten MatthewChief Financial Officer
|
OtherStock Options (Right to Buy) · Derivative | 11,450 | Not disclosed Strike: $6.37 | Not disclosed |
DisclosureSEC source: 0001562180-22-007076 · primarydocument.xml · derivative · entry 7 Buten Matthew · CIK 0001898799 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,450 Underlying: Common Shares · 11,450 shares Expires 2032-01-07 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 17:36 UTC |
Buten MatthewChief Financial Officer
|
OtherStock Options (Right to Buy) · Derivative | 1,550 | Not disclosed Strike: $6.37 | Not disclosed |
DisclosureSEC source: 0001562180-22-007076 · primarydocument.xml · derivative · entry 6 Buten Matthew · CIK 0001898799 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550 Underlying: Common Shares · 1,550 shares Expires 2032-01-07 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 17:36 UTC |
Buten MatthewChief Financial Officer
|
Tax withholdingCommon Shares | 11,042 | $7.50 | $82,815.00 |
DisclosureSEC source: 0001562180-22-007076 · primarydocument.xml · nonDerivative · entry 5 Buten Matthew · CIK 0001898799 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,796 F3 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 17:36 UTC |
Buten MatthewChief Financial Officer
|
Exercise / conversionCommon Shares | 11,450 | $6.37 | $72,936.50 |
DisclosureSEC source: 0001562180-22-007076 · primarydocument.xml · nonDerivative · entry 4 Buten Matthew · CIK 0001898799 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 17:36 UTC |
Buten MatthewChief Financial Officer
|
Exercise / conversionCommon Shares | 1,550 | $6.37 | $9,873.50 |
DisclosureSEC source: 0001562180-22-007076 · primarydocument.xml · nonDerivative · entry 3 Buten Matthew · CIK 0001898799 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 17:36 UTC |
Buten MatthewChief Financial Officer
|
OtherCommon Shares | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007076 · primarydocument.xml · nonDerivative · entry 2 Buten Matthew · CIK 0001898799 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,838 F2 · shares: Effective as of the Distribution, each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 17:36 UTC |
Buten MatthewChief Financial Officer
|
OtherCommon Shares | 3,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007076 · primarydocument.xml · nonDerivative · entry 1 Buten Matthew · CIK 0001898799 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,088 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:35 UTC Amendment |
CHILDS JOHN WDirector
|
OtherCommon Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007102 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 5,000 F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that all Common Shares acquired were directly held by the Reporting Person; however, as reflected in this amendment, a portion of the Shares acquired were indirectly held by the Reporting Person in the John W. Childs 2013 Revocable Trust. There were no other changes made to the information in the Original Filing. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:35 UTC Amendment |
CHILDS JOHN WDirector
|
OtherCommon Shares | 1,512,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007102 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,517,110 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that all Common Shares acquired were directly held by the Reporting Person; however, as reflected in this amendment, a portion of the Shares acquired were indirectly held by the Reporting Person in the John W. Childs 2013 Revocable Trust. There were no other changes made to the information in the Original Filing. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
CHILDS JOHN WDirector
|
GrantStock Options (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007078 · primarydocument.xml · derivative · entry 9 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-10-04 F4 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
CHILDS JOHN WDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 5,998 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001562180-22-007078 · primarydocument.xml · derivative · entry 8 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
CHILDS JOHN WDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 4,119 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001562180-22-007078 · primarydocument.xml · derivative · entry 7 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
CHILDS JOHN WDirector
|
OtherStock Options (Right to Buy) · Derivative | 5,998 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0001562180-22-007078 · primarydocument.xml · derivative · entry 6 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,998 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
CHILDS JOHN WDirector
|
OtherStock Options (Right to Buy) · Derivative | 4,119 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001562180-22-007078 · primarydocument.xml · derivative · entry 5 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,119 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
CHILDS JOHN WDirector
|
Tax withholdingCommon Shares | 5,507 | $7.50 | $41,302.50 |
DisclosureSEC source: 0001562180-22-007078 · primarydocument.xml · nonDerivative · entry 4 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,522,110 F2 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
CHILDS JOHN WDirector
|
Exercise / conversionCommon Shares | 5,998 | $3.56 | $21,352.88 |
DisclosureSEC source: 0001562180-22-007078 · primarydocument.xml · nonDerivative · entry 3 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,527,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
CHILDS JOHN WDirector
|
Exercise / conversionCommon Shares | 4,119 | $4.84 | $19,935.96 |
DisclosureSEC source: 0001562180-22-007078 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,521,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
CHILDS JOHN WDirector
|
OtherCommon Shares | 1,517,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007078 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,517,500 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:40 UTC Amendment |
Coric VladDirector · Chief Executive Officer
|
OtherCommon Shares | 9,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007103 · primarydocument.xml · nonDerivative · entry 4 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: 401(K) Plan Disclosed balance after: 9,565 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that all Common Shares acquired in the Distribution were directly held by the Reporting Person; however, as reflected in this amendment, a portion of the Common Shares acquired were indirectly held by the Reporting Person in the Vladimir Coric Family Trust, the Vladimir Coric Marital Trust, and the 401(K) Plan. There were no other changes made to the information in the Original Form 4. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:40 UTC Amendment |
Coric VladDirector · Chief Executive Officer
|
OtherCommon Shares | 156,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007103 · primarydocument.xml · nonDerivative · entry 3 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Marital Trust Disclosed balance after: 156,750 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that all Common Shares acquired in the Distribution were directly held by the Reporting Person; however, as reflected in this amendment, a portion of the Common Shares acquired were indirectly held by the Reporting Person in the Vladimir Coric Family Trust, the Vladimir Coric Marital Trust, and the 401(K) Plan. There were no other changes made to the information in the Original Form 4. F3 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:40 UTC Amendment |
Coric VladDirector · Chief Executive Officer
|
OtherCommon Shares | 249,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007103 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: The Vladimir Coric Family Trust Disclosed balance after: 249,130 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that all Common Shares acquired in the Distribution were directly held by the Reporting Person; however, as reflected in this amendment, a portion of the Common Shares acquired were indirectly held by the Reporting Person in the Vladimir Coric Family Trust, the Vladimir Coric Marital Trust, and the 401(K) Plan. There were no other changes made to the information in the Original Form 4. F3 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:40 UTC Amendment |
Coric VladDirector · Chief Executive Officer
|
OtherCommon Shares | 46,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007103 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622,284 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that all Common Shares acquired in the Distribution were directly held by the Reporting Person; however, as reflected in this amendment, a portion of the Common Shares acquired were indirectly held by the Reporting Person in the Vladimir Coric Family Trust, the Vladimir Coric Marital Trust, and the 401(K) Plan. There were no other changes made to the information in the Original Form 4. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Heffernan Michael ThomasDirector
|
GrantStock Options (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007086 · primarydocument.xml · derivative · entry 12 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-10-04 F5 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Heffernan Michael ThomasDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 13,100 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001562180-22-007086 · primarydocument.xml · derivative · entry 11 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 13,100 shares Expires 2020-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Heffernan Michael ThomasDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 5,998 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001562180-22-007086 · primarydocument.xml · derivative · entry 10 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Heffernan Michael ThomasDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 4,119 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001562180-22-007086 · primarydocument.xml · derivative · entry 9 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Heffernan Michael ThomasDirector
|
OtherStock Options (Right to Buy) · Derivative | 13,100 | Not disclosed Strike: $2.40 | Not disclosed |
DisclosureSEC source: 0001562180-22-007086 · primarydocument.xml · derivative · entry 8 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,100 Underlying: Common Shares · 13,100 shares Expires 2020-01-31 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Heffernan Michael ThomasDirector
|
OtherStock Options (Right to Buy) · Derivative | 5,998 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0001562180-22-007086 · primarydocument.xml · derivative · entry 7 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,998 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Heffernan Michael ThomasDirector
|
OtherStock Options (Right to Buy) · Derivative | 4,119 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001562180-22-007086 · primarydocument.xml · derivative · entry 6 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,119 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Heffernan Michael ThomasDirector
|
Tax withholdingCommon Shares | 5,507 | $7.50 | $41,302.50 |
DisclosureSEC source: 0001562180-22-007086 · primarydocument.xml · nonDerivative · entry 5 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,370 F3 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Heffernan Michael ThomasDirector
|
Exercise / conversionCommon Shares | 13,100 | $2.40 | $31,440.00 |
DisclosureSEC source: 0001562180-22-007086 · primarydocument.xml · nonDerivative · entry 4 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Heffernan Michael ThomasDirector
|
Exercise / conversionCommon Shares | 5,998 | $3.56 | $21,352.88 |
DisclosureSEC source: 0001562180-22-007086 · primarydocument.xml · nonDerivative · entry 3 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Heffernan Michael ThomasDirector
|
Exercise / conversionCommon Shares | 4,119 | $4.84 | $19,935.96 |
DisclosureSEC source: 0001562180-22-007086 · primarydocument.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Heffernan Michael ThomasDirector
|
OtherCommon Shares | 1,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007086 · primarydocument.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,660 F1 · shares: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of common shares ("Common Shares") of the Issuer (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. (Cont'd in FN2) F2 · shares: (Cont'd from FN1) As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and will subsequently be settled in Common Shares. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Gentile KimberlySVP, Clinical Operations
|
GrantStock Options (Right to buy) · Derivative | 300,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · derivative · entry 42 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 300,000 shares Expires 2032-10-04 F5 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Gentile KimberlySVP, Clinical Operations
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · derivative · entry 41 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 12,500 shares Expires 2027-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Gentile KimberlySVP, Clinical Operations
|
Exercise / conversionStock Options (Right to buy) · Derivative | 4,500 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · derivative · entry 40 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,500 shares Expires 2027-09-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Gentile KimberlySVP, Clinical Operations
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 20,716 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · derivative · entry 39 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,716 shares Expires 2027-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Gentile KimberlySVP, Clinical Operations
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 295 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · derivative · entry 38 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 295 shares Expires 2027-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Gentile KimberlySVP, Clinical Operations
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 1,542 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · derivative · entry 37 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,542 shares Expires 2028-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC |
Gentile KimberlySVP, Clinical Operations
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 30,958 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · derivative · entry 36 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 30,958 shares Expires 2028-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.